Stabilization of vulnerable carotid plaques with proprotein convertase subtilisin/kexin type 9 inhibitor alirocumab
- 36 Downloads
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors, a novel class of monoclonal antibodies, reduce low-density lipoprotein cholesterol levels and improve outcomes of myocardial infarction and stroke. However, the effects of PCSK9 inhibitors on carotid plaques remain unclear. We describe three patients treated with PCSK9 inhibitor alirocumab for progressive carotid stenosis despite lipid-lowering statin therapy. All three patients had vulnerable plaques on magnetic resonance (MR) plaque imaging. After alirocumab treatment initiation, no patients suffered stroke or adverse events, and the stabilization of the carotid plaques was observed on MR plaque imaging.
KeywordsCarotid artery Progressive Alirocumab Proprotein convertase subtilisin/kexin type 9 inhibitor Magnetic resonance imaging
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflicts of interest.
Informed consent was obtained from all patients in this case report.
- 2.Kakkos SK, Nicolaides AN, Charalambous I, Thomas D, Giannopoulos A, Naylor AR, Geroulakos G, Abbott AL (2014) Predictors and clinical significance of progression or regression of asymptomatic carotid stenosis. J Vasc Surg 59:956–967.e951. https://doi.org/10.1016/j.jvs.2013.10.073 CrossRefGoogle Scholar
- 3.Nicholls SJ, Puri R, Anderson T, Ballantyne CM, Cho L, Kastelein JJ, Koenig W, Somaratne R, Kassahun H, Yang J, Wasserman SM, Scott R, Ungi I, Podolec J, Ophuis AO, Cornel JH, Borgman M, Brennan DM, Nissen SE (2016) Effect of evolocumab on progression of coronary disease in statin-treated patients: the GLAGOV randomized clinical trial. Jama 316:2373–2384. https://doi.org/10.1001/jama.2016.16951 CrossRefGoogle Scholar
- 4.Saam T, Ferguson MS, Yarnykh VL, Takaya N, Xu D, Polissar NL, Hatsukami TS, Yuan C (2005) Quantitative evaluation of carotid plaque composition by in vivo MRI. Arterioscler Thromb Vasc Biol 25:234–239. https://doi.org/10.1161/01.atv.0000149867.61851.31 CrossRefGoogle Scholar
- 5.Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, Kuder JF, Wang H, Liu T, Wasserman SM, Sever PS, Pedersen TR (2017) Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 376:1713–1722. https://doi.org/10.1056/NEJMoa1615664 CrossRefGoogle Scholar
- 7.Sun J, Zhao XQ, Balu N, Neradilek MB, Isquith DA, Yamada K, Canton G, Crouse JR 3rd, Anderson TJ, Huston J 3rd, O’Brien K, Hippe DS, Polissar NL, Yuan C, Hatsukami TS (2017) Carotid plaque lipid content and fibrous cap status predict systemic CV outcomes: the MRI substudy in AIM-HIGH. JACC Cardiovasc Imaging 10:241–249. https://doi.org/10.1016/j.jcmg.2016.06.017 CrossRefPubMedCentralGoogle Scholar
- 8.Watanabe Y, Nagayama M, Sakata A, Okumura A, Amoh Y, Ishimori T, Nakashita S, Dodo Y (2014) Evaluation of fibrous cap rupture of atherosclerotic carotid plaque with thin-slice source images of time-of-flight MR angiography. Ann Vasc Dis 7:127–133. https://doi.org/10.3400/avd.oa.13-00101 CrossRefPubMedCentralGoogle Scholar